Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, ...
Lunit Inc. (328130.KQ) and Summit Therapeutics Inc. ( SMMT) announced a research agreement to evaluate Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumour microenvironment analysis to ...
Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use ...
Summit Therapeutics Inc. and Lunit Inc. announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit?s AI-powered pathology platform, for tumor microenvironment analysis in support of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results